Media Room
Third Quarter 2025
Third quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation will be followed by a Q&A session.
Press releases
October 22, 2025
Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
October 20, 2025
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
October 20, 2025
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
Half year 2025 financial report XBRL package
Half Year 2025 Financial Report
Sustainability Statement 2024 (ESG Report)
Registration Document 2024 (in French)